Category: Federal Forum Posters
Purpose: Highly emetogenic chemotherapy induces nausea and vomiting in at least ninety percent of patients receiving treatment. Consequences of chemotherapy-induced nausea and vomiting (CINV) include a decrease in quality of life, delays in treatment, and the need for supportive care, which may necessitate hospitalization. Patients receiving highly emetogenic chemotherapy at the James H. Quillen VA Healthcare System receive a locally derived antiemetic regimen to prevent CINV. This study will identify the local regimen’s efficacy at preventing acute and delayed nausea in highly emetogenic chemotherapy and is intended for quality improvement.
Methods: This study will retrospectively examine patients at James H. Quillen VA Healthcare System receiving highly emetogenic chemotherapy based on agents identified by National Comprehensive Cancer Network (NCCN) for high emetic risk. Each patient’s electronic health record and paper chart will be reviewed for the primary endpoint of patient reported nausea. Secondary endpoints of interest are the setting in which the patient reports nausea, supportive care administered, and delays in chemotherapy cycles secondary to nausea.
Results: not applicable
Conclusion: not applicable
Eric Schumann– Resident, James H Quillen VA Healthcare System, Johnson City, TN